Advertisement

Topics

Novartis: New Data Confirm Lucentis Efficacy And Durability Vs Aflibercept

21:50 EDT 9 Sep 2017 | FinanzNachrichten

BASEL (dpa-AFX) - Novartis (NVS) announced that one-year interim results from the Phase IV head-to-head RIVAL study comparing Lucentis (ranibizumab) versus aflibercept confirm strong efficacy and ...

Original Article: Novartis: New Data Confirm Lucentis Efficacy And Durability Vs Aflibercept

NEXT ARTICLE

More From BioPortfolio on "Novartis: New Data Confirm Lucentis Efficacy And Durability Vs Aflibercept"

Quick Search
Advertisement
 

Relevant Topic

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...